<DOC>
	<DOCNO>NCT00144326</DOCNO>
	<brief_summary>The objective study determine tiotropium ( Spiriva , Bromuro de Tiotropio ) 18 mcg daily oral inhalation compare placebo increase magnitude daily physical activity observe COPD patient , measure use accelerometer .</brief_summary>
	<brief_title>A Randomised , Double-blind , Placebo-controlled , 12 Week Trial Evaluate Effect Tiotropium Inhalation Capsules ( Spiriva ) Magnitude Exercise , Measured Using Accelerometer , Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This 3 month , multicentre , randomise , double-blind , placebo control , parallel group study compare placebo long-term effect tiotropium inhalation capsule daily physical activity patient COPD . The drug administer form inhalation capsule tiotropium placebo , take daily morning . The record daily physical activity use accelerometer carry study visit Visit 1 . The accelerometer use five day period , Thursday Monday , close correspond visit . The pulmonary function test carry Visit 1 ( screen visit ) , Visit 2 ( baseline visit ) study visit ( Visits 3 5 ) restriction detail trial protocol . Study Hypothesis : The null hypothesis difference tiotropium ( Spiriva ) placebo regard magnitude exercise measure accelerometer . The alternative hypothesis difference tiotropium ( Spiriva ) placebo regard magnitude exercise measure accelerometer . Comparison ( ) : The difference physical activity measure vector magnitude unit ( VMUs ) triaxial Stayhealthy RT3 accelerometer end three month treatment period compare placebo .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>All patient must sign Informed Consent Form consistent ICHGPC guideline prior participation trial Diagnosis COPD meet follow spirometric criterion : The patient must present relatively stable* airway obstruction An FEV1 &lt; = 65 % predict normal value FEV1 &lt; = 70 % FVC , visit 1 ( screen ) . This must confirm visit 2 ( baseline ) . Male female patient 40 year age old . The patient must smokers exsmokers history smoke least 10 packyears . The patient must able carry test related study , include slow force spirometry 6 minute walk test , exactly require protocol . The patient must able inhale medication mean HandiHaler . Those patient significant disease COPD exclude . Patients regularly use daytime oxygen therapy 1 hour per day investigator 's opinion unable abstain use oxygen therapy study . Patients respiratory tract infection past six week prior screen visit ( Visit 1 ) runin period , prior Visit 2 ( baseline ) . Patients past history asthma , allergic rhinitis atopy , present total eosinophil count &gt; = 600 mm3 . No new eosinophil count undertaken patient .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>